Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

VJVirtual | MUK Nine study: what about tolerability?

Matthew Jenner • 6 May 2020
Multiple Myeloma

Matthew Jenner, MBBS, MRCP, FRCPath, PhD, of University Hospital Southampton NHS Foundation Trust, Southampton, UK, highlights the tolerability observed in the UKMRA OPTIMUM (MUK Nine) study. This study looked at tailoring treatment for patients with high-risk newly diagnosed multiple myeloma. These data were submitted as an abstract to the BSH 2020 meeting. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Matthew Jenner

4:07
Trial updates in myeloma: COLUMBA and POLLUX
Matthew Jenner • 6 May 2020
7:27
COVID-19 changing practice in Southampton
Matthew Jenner • 6 May 2020
2:12
Treatment choice for MM in UK practice
Matthew Jenner • 6 May 2020
2:59
OPTIMISMM study update
Matthew Jenner • 6 May 2020

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals